MIA
CRL icon

MainStreet Investment Advisors’s Charles River Laboratories CRL Stock Holding History

MainStreet Investment Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,065
Closed -$465K – 162
2025
Q2 		$465K Buy
3,065
+600
+24% +$80K 0.06% 123
2025
Q1 		$371K Buy
2,465
+720
+41% +$121K 0.05% 127
2024
Q4 		$322K Sell
1,745
-92
-5% -$17.7K 0.05% 131
2024
Q3 		$362K Sell
1,837
-186
-9% -$38.7K 0.05% 130
2024
Q2 		$418K Buy
+2,023
New +$458K 0.05% 125

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MainStreet Investment Advisors's CRL Position: Q3 2025 in Review

MainStreet Investment Advisors sold out of Charles River Laboratories (CRL) in Q3 2025, closing a stake of 3,065 shares — an estimated $465K sold.

MainStreet Investment Advisors first reported a position in CRL in Q2 2024 and held it in 5 quarters. The position peaked at $465K in Q2 2025. 554 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

  • MainStreet Investment Advisors reported no remaining Charles River Laboratories position as of Q3 2025 after selling out during the quarter.
  • MainStreet Investment Advisors sold 3,065 Charles River Laboratories shares in Q3 2025, an estimated $465K.
  • MainStreet Investment Advisors first reported a position in Charles River Laboratories in Q2 2024 and held it in 5 quarters.
  • MainStreet Investment Advisors's Charles River Laboratories position peaked at $465K in Q2 2025.
  • 554 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on MainStreet Investment Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.